前哨淋巴结活检联合原发瘤临床病理特征可提高黑色素瘤分期准确性
该研究基于荷兰人群队列(n=9272)和澳大利亚验证队列(n=5644),评估前哨淋巴结(SN)状态在预测黑色素瘤生存结局中的附加价值。多变量Cox分析显示,将SN状态加入Breslow厚度、性别、年龄等临床病理特征模型后,OS的C统计量从0.74升至0.78,RFS从0.74升至0.76,验证队列结果一致,结论认为SN状态可显著提高预测准确性,但需权衡活检利弊。
要点
- 决策曲线分析显示含SN状态的模型对3年和5年死亡或复发风险分类更准确。
- 3年OS和RFS的灵敏度在开发队列均提高12%,验证队列分别提高10%和6%。
核心结论
- 在综合的 established 临床病理预后因素基础上加入SN状态,可显著提高RFS、MSS和OS的预测准确性。
- 临床医生和患者需在权衡SN活检利弊时考虑预测准确性改善的幅度。
研究设计与样本
- 基于荷兰人群的黑色素瘤患者队列(n=9272)和澳大利亚大型黑色素瘤治疗中心的验证队列(n=5644)进行数据分析。
- 纳入2004至2014年间诊断为组织学证实的原发性侵袭性皮肤黑色素瘤并接受SN活检的成人患者。
- 在荷兰队列中采用多变量Cox比例风险分析评估RFS、MSS和OS,并在澳大利亚队列中验证。
- 计算Harrell C统计量、决策曲线分析的净获益和净重分类指数(NRI)。
主要发现
- 荷兰队列中,将SN状态加入包含Breslow厚度、性别、年龄、部位、核分裂、溃疡、消退和黑色素瘤亚型的模型后,OS的C统计量从0.74提高到0.78,RFS从0.74提高到0.76。
- 澳大利亚队列中,C统计量OS从0.70提高到0.73,RFS从0.70提高到0.74,MSS从0.72提高到0.76。
- 决策曲线分析显示,包含SN状态的模型对3年和5年死亡或复发风险的分类更准确。
- 开发队列中3年OS和RFS的灵敏度均提高12%,验证队列中OS和RFS分别提高10%和6%。
临床怎么用
- 对于原发性皮肤黑色素瘤患者,在评估预后时可考虑将SN状态纳入综合临床病理特征模型以提高预测准确性。
- 临床决策中需个体化权衡SN活检的获益与 disadvantages,参考预测准确性改善的幅度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It has been claimed, without supporting evidence, that knowledge of sentinel node (SN) status does not provide more accurate prognostic information than basic clinicopathological features of a primary cutaneous melanoma. We sought to investigate this claim and to quantify any additional value of SN status in predicting survival outcome. PATIENTS AND METHODS: Data for a Dutch population-based cohort of melanoma patients (n = 9272) and for a validation cohort from a large Australian melanoma treatment center (n = 5644) were analyzed. Patients were adults diagnosed between 2004 and 2014 with histologically-proven, primary invasive cutaneous melanoma who underwent SN biopsy. Multivariable Cox proportional hazards analyses were carried out in the Dutch cohort to assess recurrence-free survival (RFS), melanoma-specific survival (MSS) and overall survival (OS). The findings were validated using the Australian cohort. Discrimination (Harrell's C-statistic), net benefit using decision curve analysis and net reclassification index (NRI) were calculated. RESULTS: The Dutch cohort showed an improved C-statistic from 0.74 to 0.78 for OS and from 0.74 to 0.76 for RFS when SN status was included in the model with Breslow thickness, sex, age, site, mitoses, ulceration, regression and melanoma subtype. In the Australian cohort, the C-statistic increased from 0.70 to 0.73 for OS, 0.70 to 0.74 for RFS and 0.72 to 0.76 for MSS. Decision curve analyses showed that the 3-year and 5-year risk of death or recurrence were more accurately classified with a model that included SN status. At 3 years, sensitivity increased by 12% for both OS and RFS in the development cohort, and by 10% and 6% for OS and RFS, respectively, in the validation cohort. CONCLUSIONS: Knowledge of SN status significantly improved the predictive accuracy for RFS, MSS and OS when added to a comprehensive suite of established clinicopathological prognostic factors. However, clinicians and patients must consider the magnitude of the improvement when weighing up the advantages and disadvantages of SN biopsy for melanoma.
引用
- El Sharouni MA, Stodell MD, Ahmed T, et al. Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. Ann Oncol. 2020. PMID: 33253862. doi:10.1016/j.annonc.2020.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。